Pioglitazone for the Treatment of Bipolar Depression

Stopped early · Phase 4 · Has a placebo group

Conditions studied: Bipolar Disorder, Insulin Resistance

In brief

The primary objective is to test the hypothesis that adjunctive pioglitazone is more effective than placebo for the relief of acute depressive symptoms resulting from bipolar disorder. The secondary objectives are to determine potential moderators and mediators of antidepressant efficacy.

Key facts

Study ID

NCT01717040

Run by

University Hospitals Cleveland Medical Center

People needed

37

Starts

2012-09-01

Expected to finish

2016-03-01

Last updated by the study team

2017-01-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Be male or female >= 18 years of age
• Diagnostic and Statistical Manual-IV (DSM-IV) diagnosis of bipolar disorder (type I, II, or NOS)
• Currently depressed as confirmed by the Mini-International Neuropsychiatric Interview (M.I.N.I.)-Plus at the screening visit
• Inventory of Depressive Symptoms total score > 25 or Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR16) > 11 at study baseline
• Women of childbearing potential (not surgically sterile or 2 years postmenopausal), must use a medically accepted method of contraception and must agree to continue use of this method for the duration of the study and for 30 days after participation in the study. Acceptable methods of contraception include barrier method with spermicide, abstinence, intrauterine device (IUD), or steroidal contraceptive (oral, transdermal, implanted, and injected) in conjunction with a barrier method.

You may not qualify if…

• Pregnant or breast feeding
• Unstable or inadequately treated medical illness as judged by the investigator
• Severe personality disorder
• Serious suicidal risk as judged by the investigator or having a score ≥ 4 on Montgomery Asberg Depression Rating Scale (MADRS) item number 10 (suicidal thoughts) at screening or baseline
• Known history of intolerance or hypersensitivity to pioglitazone
• Treatment with pioglitazone in the 3 months prior to randomization
• Dependence on alcohol or drugs (other than nicotine) in the 3 months prior to study entry
• Currently taking insulin or rosiglitazone.
• Diagnosed with dementia
• Acute Mania as defined by a Young Mania Rating Scale (YMRS) score > 15
• Diagnosed with heart failure
• Transaminase elevation >2.5 times the upper limit of normal
• Presence of renal impairment (eg. creatinine > 1.5)
• History of bladder carcinoma
• Fasting blood glucose >150 mg/dL and Hb A1c> 7%; participants meeting these criteria will be referred to an endocrinologist or their primary care physician for a diabetes evaluation and education.
• Receiving acute series of electroconvulsive therapy

Where it is running

• University Hospitals Cleveland Medical Center - Mood Disorders Program — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.